Copyright
©The Author(s) 2018.
World J Diabetes. Jun 15, 2018; 9(6): 80-91
Published online Jun 15, 2018. doi: 10.4239/wjd.v9.i6.80
Published online Jun 15, 2018. doi: 10.4239/wjd.v9.i6.80
Figure 2 Renal function after coagonist treatment in streptozotocin-high-fat and db/db mice.
A: BUN; B: Creatinine; C: Urinary albumin excretion; D: Renal triglyceride; E: Renal cholesterol; F: Renal SOD; G: Renal CAT; H: Renal TBARS. Results are shown as mean ± SE (n = 10) for each group and P < 0.05 considered to be statistically significant. HFSTZ: Streptozotocin-high-fat; BUN: Blood urea nitrogen; SOD: Superoxide dismutase; CAT: Catalase; TBARS: Thiobarbituric acid reactive substances.
- Citation: Patel VJ, Joharapurkar AA, Kshirsagar SG, Sutariya BK, Patel MS, Patel HM, Pandey DK, Bahekar RH, Jain MR. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus. World J Diabetes 2018; 9(6): 80-91
- URL: https://www.wjgnet.com/1948-9358/full/v9/i6/80.htm
- DOI: https://dx.doi.org/10.4239/wjd.v9.i6.80